Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss

Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss

Osteoporosis is characterized by bone loss and destruction of trabecular architecture, which greatly increases the burden on the healthcare system. Excessive activation of osteoclasts is an important cause of osteoporosis, and suppression of osteoclastogenesis is helpful for the treatment of osteopo...

Full description

Bibliographic Details
Main Authors: Dahu Qi, Hui Liu, Xuying Sun, Danni Luo, Meipeng Zhu, Tenghui Tao, Chenghao Gao, Chuankun Zhou, Wei Zhou, Jun Xiao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-01-01
Series:Frontiers in Pharmacology
Subjects:
pristimerin
osteoclastogenesis
MAPK
NF-κB
Nrf2
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.621110/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.621110/full

Similar Items